SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
+9.09%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$283M
AUM Growth
+$283M
(+40%)
Cap. Flow
+$73.4M
Cap. Flow
% of AUM
25.94%
Top 10 Holdings %
Top 10 Hldgs %
75.07%
Holding
61
New
12
Increased
13
Reduced
5
Closed
15
Top Buys
| 1 |
Labcorp
LH
|
$34.2M |
| 2 |
GE HealthCare
GEHC
|
$32.7M |
| 3 |
GSK
GSK
|
$17.1M |
| 4 |
Globus Medical
GMED
|
$8.64M |
| 5 |
PDCO
Patterson Companies, Inc.
PDCO
|
$8.15M |
Top Sells
| 1 |
Centene
CNC
|
$27.4M |
| 2 |
Cencora
COR
|
$20.5M |
| 3 |
Medtronic
MDT
|
$6.77M |
| 4 |
Avantor
AVTR
|
$5.99M |
| 5 |
Relay Therapeutics
RLAY
|
$3.79M |
Sector Composition
| 1 | Healthcare | 99.16% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GE HealthCare
GEHC
$33.7B
| $48.7M | 12.39% | 599,808 +402,921 | +205% | +$32.7M |
|
|
2
Labcorp
LH
$23.1B
| $34.2M | 8.71% | +141,906 | New | +$34.2M |
|
3
Cigna
CI
$80.3B
| $31.6M | 8.04% | 112,674 +25,499 | +29% | +$7.16M |
|
|
BCYC
4
Bicycle Therapeutics
BCYC
$511M
| $24.7M | 6.29% | 968,671 +1,324 | +0.1% | +$33.8K |
|
5
United Therapeutics
UTHR
$13.8B
| $17.6M | 4.49% | 79,926 +4,923 | +7% | +$1.09M |
|
|
6
GSK
GSK
$79.9B
| $17.1M | 4.35% | +479,532 | New | +$17.1M |
|
|
7
Globus Medical
GMED
$8.27B
| $12.7M | 3.22% | 212,593 +145,093 | +215% | +$8.64M |
|
8
ADC Therapeutics
ADCT
$345M
| $8.64M | 2.2% | 4,020,705 +1,860,073 | +86% | +$4M |
|
9
Viking Therapeutics
VKTX
$3.04B
| $8.55M | 2.18% | 527,657 +277,657 | +111% | +$4.5M |
|
10
Organon & Co
OGN
$2.45B
| $8.43M | 2.14% | 404,938 -66,615 | -14% | -$1.39M |
|
|
AXNX
11
DELISTED
Axonics, Inc. Common Stock
AXNX
| $8.28M | 2.11% | 164,017 +93,176 | +132% | +$4.7M |
|
|
PDCO
12
DELISTED
Patterson Companies, Inc.
PDCO
| $8.15M | 2.07% | +245,000 | New | +$8.15M |
|
13
Humana
HUM
$36.5B
| $5.81M | 1.48% | +13,000 | New | +$5.81M |
|
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$2.25B
| $5.43M | 1.38% | 877,193 +529,324 | +152% | +$3.28M |
|
|
IMGN
15
DELISTED
Immunogen Inc
IMGN
| $4.64M | 1.18% | +245,921 | New | +$4.64M |
|
16
Nektar Therapeutics
NKTR
$568M
| $4.02M | 1.02% | +6,995,381 | New | +$4.02M |
|
17
ARS Pharmaceuticals
SPRY
$1.15B
| $3.64M | 0.92% | +542,576 | New | +$3.64M |
|
|
RVNC
18
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.58M | 0.91% | +141,500 | New | +$3.58M |
|
|
MACK
19
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $3.58M | 0.91% | 290,749 +17,906 | +7% | +$220K |
|
20
X4 Pharmaceuticals
XFOR
$84.2M
| $3.39M | 0.86% | +1,749,003 | New | +$3.39M |
|
21
Savara
SVRA
$567M
| $3.23M | 0.82% | 1,010,701 +62,244 | +7% | +$199K |
|
22
Arcutis Biotherapeutics
ARQT
$1.86B
| $2.79M | 0.71% | +293,047 | New | +$2.79M |
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $2.27M | 0.58% | +6,431,349 | New | +$2.27M |
|
24
IDEAYA Biosciences
IDYA
$2.15B
| $1.75M | 0.45% | 74,594 +4,594 | +7% | +$108K |
|
|
NYXH
25
Nyxoah
NYXH
$234M
| $1.6M | 0.41% | 200,076 +11,201 | +6% | +$89.7K |
|